Date | Investors | Amount | Round |
---|---|---|---|
- | investor | €0.0 | round |
N/A | €0.0 Valuation: €0.0 | round | |
N/A | €0.0 Valuation: €0.0 | round | |
investor | €0.0 Valuation: €0.0 | round | |
investor investor | €0.0 | round | |
investor investor | €0.0 | round | |
investor | €0.0 | round | |
N/A | €0.0 Valuation: €0.0 | round | |
investor | €0.0 Valuation: €0.0 | round | |
investor | €0.0 Valuation: €0.0 | round | |
investor investor investor investor | €0.0 Valuation: €0.0 | round | |
investor investor investor investor investor | €0.0 | round | |
N/A | €0.0 Valuation: €0.0 | round | |
investor | €0.0 Valuation: €0.0 | round | |
N/A | €0.0 Valuation: €0.0 | round | |
investor | €0.0 | round | |
investor | €0.0 Valuation: €0.0 | round | |
investor | €0.0 Valuation: €0.0 | round | |
investor | €0.0 Valuation: €0.0 0.1x EV/Revenue | round | |
investor | €0.0 Valuation: €0.0 0.9x EV/Revenue | round | |
N/A | €0.0 Valuation: €0.0 0.1x EV/Revenue | round | |
investor | €0.0 Valuation: €0.0 1.1x EV/Revenue | round | |
N/A | €0.0 Valuation: €0.0 1.6x EV/Revenue | round | |
N/A | €0.0 | round | |
N/A | €0.0 | round | |
N/A | €0.0 | round | |
investor | €0.0 | round | |
N/A | €0.0 | round | |
investor | €0.0 Valuation: €0.0 0.2x EV/Revenue -1.2x EV/EBITDA | round | |
investor | €0.0 | round | |
investor | €0.0 Valuation: €0.0 1.0x EV/Revenue -1.3x EV/EBITDA | round | |
investor | €0.0 Valuation: €0.0 0.9x EV/Revenue -1.3x EV/EBITDA | round | |
investor | €0.0 Valuation: €0.0 0.1x EV/Revenue -0.1x EV/EBITDA | round | |
investor | €0.0 | round | |
* | €13.3m | Grant | |
Total Funding | 000k |
EUR | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|---|---|
Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
% profit margin | (20 %) | (104 %) | (86 %) | (72 %) | (63 %) | (109 %) | (393 %) |
EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
Source: Company filings or news article
Related Content
MetGen Oy operates as a specialized biotechnology company focused on developing and supplying industrial enzymatic solutions. Established in 2008 in Kaarina, Finland, the company was co-founded by CEO Alex Michine, a serial entrepreneur with a background in biotechnology and cleantech, and Professor Alex Azhayev. The firm's core business revolves around designing and producing robust enzymes that can withstand harsh industrial conditions, such as extreme temperatures and pH levels.
MetGen serves industries that utilize lignocellulosic biomass, including the pulp and paper, renewable chemicals, and biofuel sectors. Its business model involves creating customized enzymatic solutions tailored to specific client needs, moving away from a one-size-fits-all product offering. Revenue is generated through the sale of these enzyme solutions, technology licensing, and joint development projects. The company employs a flexible production strategy, using a network of European contract manufacturing partners to scale production, with plans for expansion into North America, South America, and Asia.
The company's flagship product portfolio, sold under the brand name MetZyme®, consists of highly active natural catalysts that accelerate chemical reactions. A key technological offering is the METNIN™ platform, which enables the enzymatic fractionation of lignin—a byproduct of pulp and biorefinery processes—into valuable 'drop-in' replacements for fossil-based chemicals like polyols and resins. This process allows clients to valorize waste streams and create higher-value biochemicals and biomaterials. MetGen's rapid development cycle, which can take an enzyme from concept to industrial scale in 6-9 months, provides a significant operational advantage.
MetGen has actively participated in collaborative research, leveraging public funding from programs like the EU's Horizon 2020 to advance its technology and build extensive value chains. The company has received numerous accolades, including being named in the Global Cleantech 100 list in 2013 and winning the Best in BioFuel / BioEnergy category at the GCCA Later Stage Awards in 2014.
Keywords: industrial enzymes, biotechnology, cleantech, lignocellulosic biomass, biorefinery solutions, pulp and paper enzymes, renewable chemicals, biofuel production, genetic engineering, enzyme technology, lignin valorization, MetZyme, METNIN, sustainable materials, bio-based chemicals, industrial catalysis, circular economy, biomass conversion, bioplastics, water treatment, Alex Michine, Finnish biotech